References
- Blakey DC, Westwood FR, Walker M, Hughes D, Davis PD, Ashton SE, Ryan AJ. Antitumour activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clinical Cancer Research 2002; 8: 1974–1983
- Davis PD, Dougherty GJ, Blakey DC, Galbraith SM, Tozer GM, Holder AL, Naylor MA, Nolan J, Stratford MR, Chaplin DJ, et al. ZD6126: A novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Research 2002; 62: 7247–7253
- Delproposto Z, LoRusso P, Morton P, Wheeler C, Barge A, Evelhoch J. MRI evaluation of the effects of thevascular-targeting agent ZD6126 on tumor vasculature [abstract]. Proceedings of the American Society of Clinical Oncology21. 2002; 440
- Gadgeel SM, LoRusso PM, Wozniak AJ, Wheeler C. A dose-escalation study of the novel vascular-targeting agent, ZD6126, in patients with solid tumours [abstract]. Proceedings of the American Society of Clinical Oncology21. 2002; 438
- Goto H, Yano S, Zhang H, Matsumori Y, Ogawa H, Blakey DC, Sone S. Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice. Cancer Research 2002; 62: 3711–3715
- Horsman MR, Murata R. Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response. International Journal of Radiation, Oncology, Biology, Physics 2003; 57: 1047–1055
- Hunter AL, Klaassen CD. Biliary excretion of colchicine. Journal of Pharmacology and Experimental Therapeutics 1974; 192: 605–617
- Judson I, Scurr M, Roberts DW, Partridge EA, D'Souza RA, Tan S. Pharmacokinetics and metabolism of ZD6126 in patients with solid tumours (In preparation). 2007
- McCarty MF, Takeda A, Stoeltzing O, Liu W, Fan F, Reinmuth N, Akagi M, Bucana C, Mansfield PF, Ryan A, et al. ZD6126 inhibits orthotopic growth and peritoneal carcinomatosis in a mouse model of human gastric cancer. British Journal of Cancer 2004; 90: 705–711
- McKillop D, Wild MJ, Butters CJ, Simcock C. Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica 1998; 28: 845–853
- Micheletti G, Poli M, Borsotti P, Martinelli M, Imberti B, Taraboletti G, Giavazzi R. Vascular-targeting activity of ZD6126, a novel tubulin-binding agent. Cancer Research 2003; 63: 1534–1537
- Radema SA, Beerepoot LV, Witteveen EO, Thomas T, Kempin S, Wheeler C. Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent. ZD6126, in patients with solid tumours [abstract]. Clinical Cancer Research 9(Suppl. 1). 2003, abst B34
- Radema SA, Beerepoot LV, Witteveen EO, Gebbink MF, Wheeler C, Voest EE. Clinical evaluation of the novel vascular-targeting agent. ZD6126: Assessment of toxicity and surrogate markers of vascular damage [abstract]. Proceedings of the American Society of Clinical Oncology 21. 2002; 439, abst B34
- Scurr M, Judson I, Brock C, O’Donnell A, Tan S, Partridge EA, D'Souza RA, Roberts DW. Assessment of metabolism, excretion and pharmacokinetics of a single dose of [14C]-ZD6126 in patients with solid malignant tumors [abstract]. Journal of Clinical Oncology 2004; 22(14S)3083
- Siemann DW, Chaplin DJ, Horsman MR. Vascular-targeting therapies for treatment of malignant disease. Cancer 2004; 100: 2491–2499
- Siemann DW, Rojiani AM. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. International Journal of Radiation, Oncology, Biology, Physics 2002; 53: 164–171
- Soltau J, Drevs J. ZD-6126 AstraZeneca. Idrugs 2004; 7: 380–387
- Tateishi T, Soucek P, Caraco Y, Guengerich FP, Wood AJJ. Colchicine biotransformation by human liver microsomes. Identification of CYP3A4 as the major isoform responsible for colchicine demethylation. Biochemical Pharmacology 1997; 53: 111–116
- Thorpe PE, Chaplin DJ, Blakey DC. Meeting Report. The first international conference on vascular targeting. Cancer Research 2003; 63: 1144–1147
- Varghese HJ, MacKenzie LT, Groom AC, Ellis CG, Ryan A, MacDonald IC, Chambers AF. In vivo videomicroscopy reveals differential effects of the vascular-targeting agent ZD6126 and the anti-angiogenic agent ZD6474 on vascular function in a liver metastasis model. Angiogenesis 2004; 7: 157–164
- Von Angerer E. New inhibitors of tubulin polymerisation. Expert Opinion on Therapeutic Patents 1999; 9: 1069–1081
- Walaszek EJ, Kocsis JJ, Leroy GV, Geiling EMK. Studies on the excretion of radioactive colchicine. Archives Internationales de Pharmacodynamie et de Therapie 1960; 125: 371–382